AJCN Tufts Nutrition Symposium, Boston Sept 24-26
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clifford, A. J
Right arrow Articles by Novotny, J. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clifford, A. J
Right arrow Articles by Novotny, J. A
Agricola
Right arrow Articles by Clifford, A. J
Right arrow Articles by Novotny, J. A
American Journal of Clinical Nutrition, Vol. 84, No. 6, 1430-1441, December 2006
© 2006 American Society for Nutrition


ORIGINAL RESEARCH COMMUNICATION

A feasibility study quantifying in vivo human {alpha}-tocopherol metabolism1,2,3

Andrew J Clifford1, Fabiana F de Moura1, Charlene C Ho1, Jennifer C Chuang1, Jennifer Follett1, James G Fadel1 and Janet A Novotny1

1 From the Departments of Nutrition (AJC, FFM, CCH, JCC, and JF) and Animal Science (JGF), University of California, Davis, Davis, CA, and the Diet and Human Performance Laboratory, US Department of Agriculture, ARS, BHNRC, Beltsville, MD (JAN)

Background: Quantitation of human vitamin E metabolism is incomplete, so we quantified RRR- and all-rac-{alpha}-tocopherol metabolism in an adult.

Objective: The objective of the study was to quantify and interpret in vivo human vitamin E metabolism.

Design: A man was given an oral dose of 0.001821 µmol [5-14CH3]RRR-{alpha}-tocopheryl acetate (with 101.5 nCi 14C), and its fate in plasma, plasma lipoproteins, urine, and feces was measured over time. Data were analyzed and interpreted by using kinetic modeling. The protocol was repeated later with 0.001667 µmol [5-14CH3]all-rac-{alpha}-tocopheryl acetate (with 99.98 nCi 14C).

Results: RRR-{alpha}-tocopheryl acetate and all-rac-{alpha}-tocopheryl acetate were absorbed equally well (fractional absorption: {approx} 0.775). The main route of elimination was urine, and {approx}90% of the absorbed dose was {alpha}-2(2'-carboxyethyl)-6-hydroxychroman. Whereas 93.8% of RRR-{alpha}-tocopherol flow to liver kinetic pool B from plasma was returned to plasma, only 80% of the flow of all-rac-{alpha}-tocopherol returned to plasma; the difference (14%) was degraded and eliminated. Thus, for newly digested {alpha}-tocopherol, the all-rac form is preferentially degraded and eliminated over the RRR form. Respective residence times in liver kinetic pool A and plasma for RRR-{alpha}-tocopherol were 1.16 and 2.19 times as long as those for all-rac-{alpha}-tocopherol. Model-estimated distributions of plasma {alpha}-tocopherol, extrahepatic tissue {alpha}-tocopherol, and liver kinetic pool B for RRR-{alpha}-tocopherol were, respectively, 6.77, 2.71, and 3.91 times as great as those for all-rac-{alpha}-tocopherol. Of the lipoproteins, HDL had the lowest 14C enrichment. Liver had 2 kinetically distinct {alpha}-tocopherol pools.

Conclusions: Both isomers were well absorbed; all-rac-{alpha}-tocopherol was preferentially degraded and eliminated in urine, the major route. RRR-{alpha}-tocopherol had a longer residence time and larger distribution than did all-rac-{alpha}-tocopherol. Liver had 2 distinct {alpha}-tocopherol pools. The model is a hypothesis, its estimates are model-dependent, and it encourages further testing.

Key Words: {alpha}-Tocopherol • isomer • human • metabolism • radiocarbon • accelerator mass spectrometry







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by The American Society for Nutrition